Amicus initiated with a Buy at Guggenheim. Guggenheim analyst Whitney Ijem started Amicus Therapeutics with a Buy rating and $18 price target. The analyst thinks Amicus shares are well positioned headed into 2019 given the ongoing Galafold launch and the company’s “robust pipeline of new gene therapy assets that will produce several updates throughout the year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.